Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases

Jerzy Lasota, Christopher L. Corless, Michael C. Heinrich, Maria Debiec-Rychter, Raf Sciot, Eva Wardelmann, Sabine Merkelbach-Bruse, Hans Ulrich Schildhaus, Sonja E. Steigen, Jerzy Stachura, Agnieszka Wozniak, Cristina Antonescu, Ondrej Daum, Javier Martin, Javier Garcia Del Muro, Markku Miettinen

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by oncogenic, mutational activation of KIT or platelet-derived growth factor receptor α (PDGFRA). GIST-specific KIT or PDGFRA mutations have been linked to tumor location, tumor cell morphology and clinical behavior. The purpose of this study was to evaluate the clinicopathologic profile of GISTs that have KIT exon 13 or exon 17 mutations. Through the collaboration of several GIST research groups, we gathered 54 cases from the pre-imatinib era that had such primary mutations. From our observations and those in the literature, we estimate that the frequency of these mutations is no higher than 1-2%. Almost all (32 of 33, 97%) of the KIT exon 13 mutations were the 1945A>G substitution leading to Lys642Glu. A majority (15 of 21, 71.4%) of the KIT exon 17 mutations were the 2487T>A substitution leading to Asn822Lys. Demographic and clinicopathologic data were available for 26 and 14 KIT exon 13 and exon 17 mutant GISTs, respectively. Median age and male to female ratio were similar to ones reported in other GIST studies. Small intestinal tumors were two times more frequent than gastric ones among KIT exon 17 mutants. Also, intestinal tumors were slightly overrepresented among KIT exon 13 mutants when compared with population-based studies. The majority of KIT exon 13 or exon 17 mutants had a spindle-cell morphology and only a few had epithelioid features. Tumor size varied from 1.2 to 25 cm and average mitotic rates were 9.5 and 4.2 for KIT exon 13 and exon 17 mutants, respectively. Gastric KIT exon 13 mutant GISTs tend to be slightly larger and more aggressive than gastric GISTs in average, whereas the behavior of small intestinal GISTs with KIT exon 13 mutations does not differ from other small intestinal GISTs. The latter is also true for all KIT exon 17 mutant GISTs.

Original languageEnglish (US)
Pages (from-to)476-484
Number of pages9
JournalModern Pathology
Volume21
Issue number4
DOIs
StatePublished - Apr 1 2008

    Fingerprint

Keywords

  • GIST
  • KIT
  • Mutation
  • Tyrosine kinase domain

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lasota, J., Corless, C. L., Heinrich, M. C., Debiec-Rychter, M., Sciot, R., Wardelmann, E., Merkelbach-Bruse, S., Schildhaus, H. U., Steigen, S. E., Stachura, J., Wozniak, A., Antonescu, C., Daum, O., Martin, J., Del Muro, J. G., & Miettinen, M. (2008). Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases. Modern Pathology, 21(4), 476-484. https://doi.org/10.1038/modpathol.2008.2